WO2007110339A1 - Anti-igf-1r human monoclonal antibody formulation - Google Patents
Anti-igf-1r human monoclonal antibody formulation Download PDFInfo
- Publication number
- WO2007110339A1 WO2007110339A1 PCT/EP2007/052569 EP2007052569W WO2007110339A1 WO 2007110339 A1 WO2007110339 A1 WO 2007110339A1 EP 2007052569 W EP2007052569 W EP 2007052569W WO 2007110339 A1 WO2007110339 A1 WO 2007110339A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- igf
- histidine
- mlhumab
- polysorbate
- nacl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009502016A JP2009531371A (en) | 2006-03-28 | 2007-03-19 | Anti-IGF-1R human monoclonal antibody preparation |
AU2007229554A AU2007229554A1 (en) | 2006-03-28 | 2007-03-19 | Anti-IGF-1R human monoclonal antibody formulation |
EP07727047A EP1998806A1 (en) | 2006-03-28 | 2007-03-19 | Anti-igf-1r human monoclonal antibody formulation |
BRPI0709229-6A BRPI0709229A2 (en) | 2006-03-28 | 2007-03-19 | anti-igf-ir human monoclonal antibody formulation |
CA002647111A CA2647111A1 (en) | 2006-03-28 | 2007-03-19 | Anti-igf-1r human monoclonal antibody formulation |
MX2008012295A MX2008012295A (en) | 2006-03-28 | 2007-03-19 | Anti-igf-1r human monoclonal antibody formulation. |
IL193904A IL193904A0 (en) | 2006-03-28 | 2008-09-04 | Anti-igf-1r human monoclonal antibody formulation |
NO20083895A NO20083895L (en) | 2006-03-28 | 2008-09-11 | Anti-IGF-1R human monoclonal antibody formulation |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06111848.5 | 2006-03-28 | ||
EP06111848 | 2006-03-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007110339A1 true WO2007110339A1 (en) | 2007-10-04 |
Family
ID=37025222
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2007/052569 WO2007110339A1 (en) | 2006-03-28 | 2007-03-19 | Anti-igf-1r human monoclonal antibody formulation |
Country Status (18)
Country | Link |
---|---|
EP (1) | EP1998806A1 (en) |
JP (1) | JP2009531371A (en) |
KR (1) | KR20080104160A (en) |
CN (1) | CN101410137A (en) |
AR (1) | AR060130A1 (en) |
AU (1) | AU2007229554A1 (en) |
BR (1) | BRPI0709229A2 (en) |
CA (1) | CA2647111A1 (en) |
CL (1) | CL2007000797A1 (en) |
CR (1) | CR10295A (en) |
EC (1) | ECSP088778A (en) |
IL (1) | IL193904A0 (en) |
MA (1) | MA30345B1 (en) |
MX (1) | MX2008012295A (en) |
NO (1) | NO20083895L (en) |
RU (1) | RU2008142359A (en) |
TW (1) | TW200815029A (en) |
WO (1) | WO2007110339A1 (en) |
Cited By (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008071394A1 (en) * | 2006-12-11 | 2008-06-19 | F. Hoffmann-La Roche Ag | Abeta antibody parenteral formulation |
WO2008098917A2 (en) * | 2007-02-14 | 2008-08-21 | Glaxo Group Limited | Novel antibodies against igf-ir |
WO2009007272A1 (en) * | 2007-07-10 | 2009-01-15 | F. Hoffmann-La Roche Ag | Novel formulation |
WO2009068282A1 (en) * | 2007-11-29 | 2009-06-04 | F. Hoffmann-La Roche Ag | Immunoglobulin aggregates |
US20090162352A1 (en) * | 2007-12-21 | 2009-06-25 | Michael Adler | Antibody formulation |
EP2136839A2 (en) * | 2007-03-22 | 2009-12-30 | Imclone LLC | Stable antibody formulations |
WO2010069858A1 (en) * | 2008-12-19 | 2010-06-24 | F. Hoffmann-La Roche Ag | Pharmaceutical composition |
WO2010146059A2 (en) | 2009-06-16 | 2010-12-23 | F. Hoffmann-La Roche Ag | Biomarkers for igf-1r inhibitor therapy |
WO2016057739A1 (en) * | 2014-10-09 | 2016-04-14 | Regeneron Pharmaceuticals, Inc. | Process for reducing subvisible particles in a pharmaceutical formulation |
US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
CN106999591A (en) * | 2015-09-28 | 2017-08-01 | 江苏恒瑞医药股份有限公司 | A kind of antibody preparations of anti-PD 1 and its in application pharmaceutically |
EP2691112B1 (en) | 2011-03-31 | 2018-05-23 | Merck Sharp & Dohme Corp. | Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments |
US10280227B2 (en) | 2009-09-11 | 2019-05-07 | Genentech, Inc. | Highly concentrated pharmaceutical formulations |
US10941205B2 (en) | 2015-10-02 | 2021-03-09 | Hoffmann-La Roche Inc. | Bispecific anti-human A-beta/human transferrin receptor antibodies and methods of use |
US11091541B2 (en) | 2013-04-29 | 2021-08-17 | Hoffmann-La Roche Inc. | Human FcRn-binding modified antibodies and methods of use |
CN114324882A (en) * | 2020-10-12 | 2022-04-12 | 广东菲鹏生物有限公司 | Protein stabilizer and application thereof |
US11333642B2 (en) | 2016-10-25 | 2022-05-17 | Regeneran Pharmaceuticals, Inc. | Methods and systems for chromatography data analysis |
US11369896B2 (en) | 2016-08-16 | 2022-06-28 | Regeneron Pharmaceuticals, Inc. | Methods for quantitating individual antibodies from a mixture |
US11555067B2 (en) | 2014-01-15 | 2023-01-17 | Hoffmann-La Roche Inc. | Fc-region variants with improved protein A-binding |
US11584793B2 (en) | 2015-06-24 | 2023-02-21 | Hoffmann-La Roche Inc. | Anti-transferrin receptor antibodies with tailored affinity |
US11603411B2 (en) | 2015-10-02 | 2023-03-14 | Hoffmann-La Roche Inc. | Bispecific anti-human CD20/human transferrin receptor antibodies and methods of use |
US11633476B2 (en) | 2017-05-02 | 2023-04-25 | Merck Sharp & Dohme Llc | Stable formulations of programmed death receptor 1 (PD-1) antibodies and methods of use thereof |
US11845798B2 (en) | 2017-05-02 | 2023-12-19 | Merck Sharp & Dohme Llc | Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies |
US11884698B2 (en) | 2018-07-02 | 2024-01-30 | Regeneron Pharmaceuticals, Inc. | Systems and methods for preparing a polypeptide from a mixture |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110158987A1 (en) * | 2009-12-29 | 2011-06-30 | F. Hoffmann-Laroche Ag | Novel antibody formulation |
US20130136733A1 (en) * | 2010-05-28 | 2013-05-30 | Novo Nordisk A/S | Stable Multi-Dose Compositions Comprising an Antibody and a Preservative |
CN102363040B (en) * | 2011-10-21 | 2013-05-01 | 北京锐瑟科技有限公司 | Antimicrobial peptide preparation for mucosal tissues |
CN103505729B (en) * | 2013-05-24 | 2015-10-28 | 华北制药集团新药研究开发有限责任公司 | A kind of stable rabies virus human antibody combination preparation |
CN104707146B (en) * | 2013-12-16 | 2019-04-16 | 浙江海正药业股份有限公司 | A kind of pharmaceutical composition containing adalimumab |
US10206878B2 (en) * | 2014-05-28 | 2019-02-19 | Nono Inc. | Lyophilized formulation of TAT-NR2B9C with acetylation scavenger |
CN106199007B (en) * | 2016-08-03 | 2017-04-05 | 烟台普罗吉生物科技发展有限公司 | Protein protective agent |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998056418A1 (en) * | 1997-06-13 | 1998-12-17 | Genentech, Inc. | Stabilized antibody formulation |
US20030113316A1 (en) * | 2001-07-25 | 2003-06-19 | Kaisheva Elizabet A. | Stable lyophilized pharmaceutical formulation of IgG antibodies |
WO2004087756A2 (en) * | 2003-04-02 | 2004-10-14 | F. Hoffmann-La Roche Ag | Antibodies against insulin-like growth factor i receptor and uses thereof |
WO2004091658A1 (en) * | 2003-04-04 | 2004-10-28 | Genentech, Inc. | High concentration antibody and protein formulations |
WO2005005635A2 (en) * | 2003-07-10 | 2005-01-20 | F. Hoffmann-La Roche Ag | Antibodies against insulin-like growth factor i receptor and uses thereof |
US20050069539A1 (en) * | 2003-08-13 | 2005-03-31 | Pfizer Inc | Modified human IGF-IR antibodies |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR032028A1 (en) * | 2001-01-05 | 2003-10-22 | Pfizer | ANTIBODIES AGAINST THE RECEIVER OF THE SIMILAR TO INSULIN GROWTH FACTOR |
-
2007
- 2007-03-19 KR KR1020087023673A patent/KR20080104160A/en not_active Application Discontinuation
- 2007-03-19 RU RU2008142359/15A patent/RU2008142359A/en not_active Application Discontinuation
- 2007-03-19 BR BRPI0709229-6A patent/BRPI0709229A2/en not_active IP Right Cessation
- 2007-03-19 CN CNA2007800114320A patent/CN101410137A/en active Pending
- 2007-03-19 WO PCT/EP2007/052569 patent/WO2007110339A1/en active Application Filing
- 2007-03-19 AU AU2007229554A patent/AU2007229554A1/en not_active Abandoned
- 2007-03-19 MX MX2008012295A patent/MX2008012295A/en active IP Right Grant
- 2007-03-19 CA CA002647111A patent/CA2647111A1/en not_active Abandoned
- 2007-03-19 JP JP2009502016A patent/JP2009531371A/en active Pending
- 2007-03-19 EP EP07727047A patent/EP1998806A1/en not_active Withdrawn
- 2007-03-26 TW TW096110388A patent/TW200815029A/en unknown
- 2007-03-26 CL CL2007000797A patent/CL2007000797A1/en unknown
- 2007-03-26 AR ARP070101241A patent/AR060130A1/en not_active Application Discontinuation
-
2008
- 2008-09-04 IL IL193904A patent/IL193904A0/en unknown
- 2008-09-11 NO NO20083895A patent/NO20083895L/en not_active Application Discontinuation
- 2008-09-17 CR CR10295A patent/CR10295A/en not_active Application Discontinuation
- 2008-09-26 EC EC2008008778A patent/ECSP088778A/en unknown
- 2008-10-20 MA MA31308A patent/MA30345B1/en unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998056418A1 (en) * | 1997-06-13 | 1998-12-17 | Genentech, Inc. | Stabilized antibody formulation |
US20030113316A1 (en) * | 2001-07-25 | 2003-06-19 | Kaisheva Elizabet A. | Stable lyophilized pharmaceutical formulation of IgG antibodies |
WO2004087756A2 (en) * | 2003-04-02 | 2004-10-14 | F. Hoffmann-La Roche Ag | Antibodies against insulin-like growth factor i receptor and uses thereof |
WO2004091658A1 (en) * | 2003-04-04 | 2004-10-28 | Genentech, Inc. | High concentration antibody and protein formulations |
WO2005005635A2 (en) * | 2003-07-10 | 2005-01-20 | F. Hoffmann-La Roche Ag | Antibodies against insulin-like growth factor i receptor and uses thereof |
US20050069539A1 (en) * | 2003-08-13 | 2005-03-31 | Pfizer Inc | Modified human IGF-IR antibodies |
Non-Patent Citations (2)
Title |
---|
B. COHEN ET AL.: "Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871.", CLINICAL CANCER RESEARCH, vol. 11, no. 5, 1 March 2005 (2005-03-01), U.S.A., pages 2063 - 2073, XP002433667 * |
D. BURTRUM ET AL.: "A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo.", CANCER RESEARCH, vol. 63, no. 24, 15 December 2003 (2003-12-15), U.S.A., pages 8912 - 8921, XP002316542 * |
Cited By (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008071394A1 (en) * | 2006-12-11 | 2008-06-19 | F. Hoffmann-La Roche Ag | Abeta antibody parenteral formulation |
WO2008098917A2 (en) * | 2007-02-14 | 2008-08-21 | Glaxo Group Limited | Novel antibodies against igf-ir |
WO2008098917A3 (en) * | 2007-02-14 | 2008-10-09 | Glaxo Group Ltd | Novel antibodies against igf-ir |
EP2136839A2 (en) * | 2007-03-22 | 2009-12-30 | Imclone LLC | Stable antibody formulations |
EP2136839A4 (en) * | 2007-03-22 | 2010-04-07 | Imclone Llc | Stable antibody formulations |
WO2009007272A1 (en) * | 2007-07-10 | 2009-01-15 | F. Hoffmann-La Roche Ag | Novel formulation |
WO2009068282A1 (en) * | 2007-11-29 | 2009-06-04 | F. Hoffmann-La Roche Ag | Immunoglobulin aggregates |
US20090162352A1 (en) * | 2007-12-21 | 2009-06-25 | Michael Adler | Antibody formulation |
JP2011506538A (en) * | 2007-12-21 | 2011-03-03 | エフ.ホフマン−ラ ロシュ アーゲー | Antibody formulation |
KR101247418B1 (en) * | 2007-12-21 | 2013-03-25 | 에프. 호프만-라 로슈 아게 | Antibody formulation |
WO2010069858A1 (en) * | 2008-12-19 | 2010-06-24 | F. Hoffmann-La Roche Ag | Pharmaceutical composition |
WO2010146059A2 (en) | 2009-06-16 | 2010-12-23 | F. Hoffmann-La Roche Ag | Biomarkers for igf-1r inhibitor therapy |
US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
US10377831B2 (en) | 2009-09-11 | 2019-08-13 | Genentech, Inc. | Highly concentrated pharmaceutical formulations |
US10752696B2 (en) | 2009-09-11 | 2020-08-25 | Genentech, Inc. | Highly concentrated pharmaceutical formulations |
US10280227B2 (en) | 2009-09-11 | 2019-05-07 | Genentech, Inc. | Highly concentrated pharmaceutical formulations |
EP2691112B1 (en) | 2011-03-31 | 2018-05-23 | Merck Sharp & Dohme Corp. | Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments |
US11091541B2 (en) | 2013-04-29 | 2021-08-17 | Hoffmann-La Roche Inc. | Human FcRn-binding modified antibodies and methods of use |
US11555067B2 (en) | 2014-01-15 | 2023-01-17 | Hoffmann-La Roche Inc. | Fc-region variants with improved protein A-binding |
US10342876B2 (en) | 2014-10-09 | 2019-07-09 | Regeneron Pharmaceuticals, Inc. | Process for reducing subvisible particles in a pharmaceutical formulation |
WO2016057739A1 (en) * | 2014-10-09 | 2016-04-14 | Regeneron Pharmaceuticals, Inc. | Process for reducing subvisible particles in a pharmaceutical formulation |
US11584793B2 (en) | 2015-06-24 | 2023-02-21 | Hoffmann-La Roche Inc. | Anti-transferrin receptor antibodies with tailored affinity |
CN106999591A (en) * | 2015-09-28 | 2017-08-01 | 江苏恒瑞医药股份有限公司 | A kind of antibody preparations of anti-PD 1 and its in application pharmaceutically |
RU2731418C2 (en) * | 2015-09-28 | 2020-09-02 | Сучжоу Санкадия Биофармасьютикалз Ко., Лтд. | Stable pharmaceutical preparation based on the pd-1 antibody and its use in medicine |
EP3357508A4 (en) * | 2015-09-28 | 2019-04-24 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Stable anti-pd-1 antibody pharmaceutical preparation and application thereof in medicine |
US11603411B2 (en) | 2015-10-02 | 2023-03-14 | Hoffmann-La Roche Inc. | Bispecific anti-human CD20/human transferrin receptor antibodies and methods of use |
US10941205B2 (en) | 2015-10-02 | 2021-03-09 | Hoffmann-La Roche Inc. | Bispecific anti-human A-beta/human transferrin receptor antibodies and methods of use |
US11369896B2 (en) | 2016-08-16 | 2022-06-28 | Regeneron Pharmaceuticals, Inc. | Methods for quantitating individual antibodies from a mixture |
US11571636B2 (en) | 2016-08-16 | 2023-02-07 | Regeneron Pharmaceuticals, Inc. | Methods for quantitating individual antibodies from a mixture |
US11850535B2 (en) | 2016-08-16 | 2023-12-26 | Regeneron Pharmaceuticals, Inc. | Methods for quantitating individual antibodies from a mixture |
US11333642B2 (en) | 2016-10-25 | 2022-05-17 | Regeneran Pharmaceuticals, Inc. | Methods and systems for chromatography data analysis |
US11680930B2 (en) | 2016-10-25 | 2023-06-20 | Regeneron Pharmaceuticals, Inc. | Methods and systems for chromatography data analysis |
US11633476B2 (en) | 2017-05-02 | 2023-04-25 | Merck Sharp & Dohme Llc | Stable formulations of programmed death receptor 1 (PD-1) antibodies and methods of use thereof |
US11845798B2 (en) | 2017-05-02 | 2023-12-19 | Merck Sharp & Dohme Llc | Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies |
US11884698B2 (en) | 2018-07-02 | 2024-01-30 | Regeneron Pharmaceuticals, Inc. | Systems and methods for preparing a polypeptide from a mixture |
CN114324882A (en) * | 2020-10-12 | 2022-04-12 | 广东菲鹏生物有限公司 | Protein stabilizer and application thereof |
Also Published As
Publication number | Publication date |
---|---|
AR060130A1 (en) | 2008-05-28 |
JP2009531371A (en) | 2009-09-03 |
ECSP088778A (en) | 2008-10-31 |
EP1998806A1 (en) | 2008-12-10 |
KR20080104160A (en) | 2008-12-01 |
CA2647111A1 (en) | 2007-10-04 |
CL2007000797A1 (en) | 2008-01-25 |
MX2008012295A (en) | 2008-10-09 |
MA30345B1 (en) | 2009-04-01 |
CN101410137A (en) | 2009-04-15 |
BRPI0709229A2 (en) | 2011-06-28 |
TW200815029A (en) | 2008-04-01 |
CR10295A (en) | 2008-10-06 |
IL193904A0 (en) | 2011-08-01 |
NO20083895L (en) | 2008-10-24 |
AU2007229554A1 (en) | 2007-10-04 |
RU2008142359A (en) | 2010-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1998806A1 (en) | Anti-igf-1r human monoclonal antibody formulation | |
US20100158919A1 (en) | Pharmaceutical Composition | |
KR102614259B1 (en) | Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments | |
JP2020518599A (en) | Stable preparation of programmed death receptor 1 (PD-1) antibody and method of using the same | |
US20100158925A1 (en) | Lyophilized formulations of anti-egfr antibodies | |
US20100260766A1 (en) | Stable antibody formulations | |
KR20180100439A (en) | A pharmaceutical composition comprising a bispecific antibody construct | |
TW201420601A (en) | Stable formulations of antibodies to TSLP | |
WO2007095337A2 (en) | Antibody formulation | |
TWI761869B (en) | Formulation containing anti-cd47 / pd-l1 bispecific antibody and preparation and use thereof | |
CN112822999A (en) | CSF-1R antibody formulations | |
JP2023538669A (en) | Pharmaceutical formulations containing BITE, bispecific antibodies, and methionine | |
JP7475335B2 (en) | CSF-1R antibody preparation | |
KR20220044286A (en) | Formulations comprising anti-PD-1/HER2 bispecific antibodies, methods for their preparation and uses | |
CN114832102A (en) | Stable anti-EGFR antibody composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07727047 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007727047 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 570970 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 193904 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12008502001 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007229554 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: CR2008-010295 Country of ref document: CR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2647111 Country of ref document: CA Ref document number: 08100204 Country of ref document: CO |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008091593 Country of ref document: EG |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/a/2008/012295 Country of ref document: MX Ref document number: 2009502016 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 5187/CHENP/2008 Country of ref document: IN Ref document number: 1020087023673 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200780011432.0 Country of ref document: CN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2007229554 Country of ref document: AU Date of ref document: 20070319 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2008142359 Country of ref document: RU Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: PI0709229 Country of ref document: BR Kind code of ref document: A2 Effective date: 20080926 |